Second-Line Drug Susceptibilities of Multidrug-Resistant Mycobacterium tuberculosis Isolates in Aegean Region - Turkey

Aim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard short-course regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need for second-line drugs. In such situations, drug susceptibility testing is necessary to select an appropriate treatment regimen. Unfortunately, there are few studies showing the pattern of the second-line drug resistance in Turkey. We aimed to analyze the resistance to second-line anti-tuberculosis drugs of MDR strains of Mycobacterium tuberculosis isolated from the Aegean region of Turkey. Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system. Capreomycin, ethionamide, kanamycin, amikacin, clofazimine and ofloxacin were tested in 1.25 µg/ml, 1.25 µg/ml, 5.0 µg/ml, 1.0 µg/ml, 0.5 µg/ml, and 2.0 µg/ml concentrations, respectively. Results: The results showed that 37.5% of the strains were resistant to ethionamide, 25% to capreomycin, 5% to kanamycin, amikacin and ofloxacin, and 2.5% to clofazimine. One (2.5%) of the 40 MDR-TB cases was defined as extensively drug-resistant tuberculosis (XDR-TB). Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region.

Second-Line Drug Susceptibilities of Multidrug-Resistant Mycobacterium tuberculosis Isolates in Aegean Region - Turkey

Aim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard short-course regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need for second-line drugs. In such situations, drug susceptibility testing is necessary to select an appropriate treatment regimen. Unfortunately, there are few studies showing the pattern of the second-line drug resistance in Turkey. We aimed to analyze the resistance to second-line anti-tuberculosis drugs of MDR strains of Mycobacterium tuberculosis isolated from the Aegean region of Turkey. Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system. Capreomycin, ethionamide, kanamycin, amikacin, clofazimine and ofloxacin were tested in 1.25 µg/ml, 1.25 µg/ml, 5.0 µg/ml, 1.0 µg/ml, 0.5 µg/ml, and 2.0 µg/ml concentrations, respectively. Results: The results showed that 37.5% of the strains were resistant to ethionamide, 25% to capreomycin, 5% to kanamycin, amikacin and ofloxacin, and 2.5% to clofazimine. One (2.5%) of the 40 MDR-TB cases was defined as extensively drug-resistant tuberculosis (XDR-TB). Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region.

___

  • 1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report 3. The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance. WHO/HTM/TB/ 2004.343. Geneva, Switzerland: WHO; 2004. pp. 21-83.
  • 2. MMWR. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000- 2004. Morb Mortal Wkly Rep 2006 Mar 24; 55(11): 301-5.
  • 3. Pfyffer GE, Bonato DA, Ebrahımzadeh A, Gross W, Hotaling J, Kornblum J et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-86.
  • 4. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; Approved Standard, NCCLS document M24-A, Pennsylvania USA, 2003. p. 5.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK